Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer

Anti-PD-1/PD-L1 immunotherapy, as a treatment for many tumors, has shown good efficacy. However, responses to immunotherapy did not always occur or last long., i.e. primary or acquired resistance, even tumors were PD-L1 positive. Several oncogenic pathways, including PI3K/AKT activation by PTEN loss...

Full description

Saved in:
Bibliographic Details
Published in:Am J Cancer Res
Main Authors: Choi, Junyoung, Lee, Hee Jin, Yoon, Shinkyo, Ryu, Hyun-Min, Lee, Eunjin, Jo, Yujin, Seo, Seyoung, Kim, Deokhoon, Lee, Chang Hoon, Kim, Wanlim, Ha, Joo Young, Kim, Soo-Youl, Gong, Gyungyub, Jung, Kyung Hae, Park, Sook Ryun, Kim, Sang-We, Park, Kang-Seo, Lee, Dae Ho
Format: Artigo
Language:Inglês
Published: e-Century Publishing Corporation 2020
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539780/
https://ncbi.nlm.nih.gov/pubmed/33042623
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items